GSK
GSK plc
Stock
$47.03−0.15 (−0.32%)Close Oct 2, 2026
Cash flow statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | £7.7B | £6.6B | £6.8B | £7.4B | £8.0B | £8.4B | £8.0B | £8.4B | £6.9B | £6.5B | £2.6B |
| Capital expenditures | £1.3B | £1.4B | £1.3B | £1.1B | £950M | £989M | £1.3B | £1.3B | £1.5B | £1.5B | £1.4B |
| Free cash flow | £6.4B | £5.2B | £5.5B | £6.3B | £7.0B | £7.5B | £6.8B | £7.1B | £5.4B | £5.0B | £1.2B |
| Stock-based compensation | £374M | £344M | £307M | £346M | £343M | £337M | £365M | £360M | £333M | £319M | £368M |
| Buybacks | £1.4B | £0 | £0 | — | — | — | — | — | — | — | — |
| Dividends paid | £2.6B | £2.4B | £2.2B | £3.5B | £4.0B | £4.0B | £4.0B | £3.9B | −£3.9B | £4.9B | £3.9B |
| Free cash flow margin | 19.6% | 16.4% | 18.0% | 21.3% | 28.4% | 30.6% | 20.0% | 23.0% | 17.8% | 17.8% | 5.0% |